A big change is under way in pharma industries in the world. Global pharmas with over 100 year histories rarely develop new drugs by themselves any more, but their main strategy is to buy either good seeds or small companies that hold them. Recently, a new pharmaceutical company that buy either seeds with high success rates or small companies that hold them appeared in Silicon Valley, and may overwhelm some global pharmas. It means that the former business model of developing new drugs focusing on chemicals and animal experiments is not successful any more, and the most important step in developing a new drug is to predict the success rate of each seed accurately.
Success and failure in new drug development are judged by safety and efficacy in humans. Naoyuki Kamatani, the chairman of our company has proposed a method of new drug development based on genomic studies of diseases like genetic diseases for more than 30 years. For example, he has been involved in the developments of cladribine, febuxostat and personalized treatment for MTAP deficient tumors, and all of them incorporated important ideas from the results of genomic studies of diseases. The former two drugs have been successfully marketed in the world. Recent successful new drug developments by others have also incorporated ideas from the results of genomic studies. Examples are SGLT2 inhibitors, anti-PCSK9 antiboties, anti-RANKL antibodies, eye drops containing lanosterol and personalized anti-cancer treatments. This is because the effects of the changes of human genes on proteins can accurately predict the effects of drugs on the same proteins.
StaGen Co, LTD evaluates the success rate of a seed based on the results of human genomic studies, and promotes new drug development and drug repositioning with high success rates.
StaGen has submitted two patents for new drugs, and holds three for pharmacogenomics.